Module Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET
To learn if TKI258 (the study drug) is safe and has beneficial effects in people who have different types of cancer with pre-identified mutations or translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk, or RET
Select solid tumors and hematologic malignancies with one of the tumor pathway activations listed above.
1. Male or female of at least 18 years of age.
2. Diagnosis of select solid tumor (except urothelial tumors, hepatocellular carcinoma, endometrial carcinoma, metastatic breast cancer, squamous NSCLC, or renal cell carcinoma) or hematologic malignancy (except for FLT3 AML and multiple myeloma).
3. Pre-identified FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk, or RET mutation or translocation.
4. Received at least one prior treatment for recurrent, metaastatic, and/or locally advanced disease.
5. Other criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression or development of unacceptable side effects
Knight Clinical Trials Information Line